Camber Capital Management’s AstraZeneca AZN Stock Holding History

Camber Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-750,000	Closed	-$90.1M	–	40
2021 Q3	$90.1M	Sell	750,000 -250,000	-25%	-$29.1M	2.77%	15
2021 Q2	$120M	Buy	+1,000,000	New	+$110M	4.04%	7
2015 Q4	–	Sell	-920,587	Closed	-$3K	–	49
2015 Q3	$3K	Buy	+920,587	New	+$60.6M	﹤0.01%	44

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Camber Capital Management's AZN Position: Q1 2016 in Review

Camber Capital Management sold out of AstraZeneca (AZN) in Q1 2016, closing a stake of 1,000,000 shares — an estimated $67.9M sold.

Camber Capital Management first reported a position in AZN in Q3 2013 and held it in 4 quarters. The position peaked at $79.6M in Q2 2015. 390 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

Camber Capital Management reported no remaining AstraZeneca position as of Q1 2016 after selling out during the quarter.
Camber Capital Management sold 1,000,000 AstraZeneca shares in Q1 2016, an estimated $67.9M.
Camber Capital Management first reported a position in AstraZeneca in Q3 2013 and held it in 4 quarters.
Camber Capital Management's AstraZeneca position peaked at $79.6M in Q2 2015.
390 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on Camber Capital Management's 13F filing for Q1 2016, filed 13 May 2016.